Phase 2 N=15 Use of Pancreatic Enzymes in Short Bowel Syndrome
Short Bowel Syndrome
Primary: Change in Coefficient of Fat Absorption — 2.3 percentage of fat absorbed
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=48 Comparison of Smoflipid to Soy-based Lipid Reduction for Cholestasis Prevention in Surgical Neonates
Cholestasis of Parenteral Nutrition
Primary: Number of Participants With Cholestasis — 1; 3; 7 Participants — p=0.590
Phase 2 N=18 Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies
Prematurity · Intestine Perforation · Necrotizing Enterocolitis (NEC)
Primary: The Serum Biomarkers of Inflammatory Cytokines
Phase 2 N=60 Fecal Microbiota Transplantation for Pancreatitis
Acute Pancreatitis · Intestinal Bacteria Flora Disturbance · Intestinal Dysfunction
Primary: Number of Participants With Gastrointestinal Failure Score Equal 0 — 12; 14 Participants
Phase 4 N=15 rHGH and Intestinal Permeability in Intestinal Failure
Short Bowel Syndrome
Primary: To Identify Small Intestinal Permeability Changes in Short Bowel Syndrome Patients After Administration of Recombinant Human Growth Hormone (Zorbtive®). — 7 participants
Phase 1 N=44 Intestinal Permeability in Preterm Infants
Prematurity · Intestinal Permeability
Primary: Intestinal Permeability — 0.0731; 0.0720 ratio — p=0.932
Phase 2 N=9 Metabolic Balance Study of Apraglutide in Patients With Short Bowel Syndrome, Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC)
Short Bowel Syndrome
Primary: Number of Participants Who Experienced a Treatment-Emergent Adverse Event (TEAE) — 9; 5; 3; 1 Participants
N/A N=36 Nutritional Status and Enteral Absorption Capability After Brain Death
Brain Death
Primary: Primary Outcome Measure is IL-6 Level — 565.5; 264.9 pg/ml
Phase 1 N=23 Fecal Microbiota Transplantation in Pediatric Patients
Inflammatory Bowel Diseases (IBD) · Crohn's Disease (CD) · Ulcerative Colitis (UC)
Primary: Number of Occurrences of Adverse Events at 6 Months According to Adverse Event Term — 11; 5; 5; 3 Events
N/A N=40 A More Physiological Feeding Process in ICU:the Intermittent Infusion With Semi-solidification of Nutrients
Nutrition, Enteral
Primary: the Ratio of the Enteral Nutrition — 0.98; 0.73 ratio
N/A N=529 Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis
Infant, Newborn · Infant, Low Birth Weight · Infant, Small for Gestational Age
Primary: Death or Neurodevelopmental Impairment (NDI) — 44; 46; 27; 28 Participants — p=0.03
Phase 2 N=6 8.4% Sodium Bicarbonate Locks in Intestinal Failure
Intestinal Failure · CRBSI - Catheter Related Bloodstream Infection
Primary: Rate of Catheter Related Bloodstream Infections — 8.2; 3.0 infections per 1000 catheter days
N/A N=9 Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants
Bloodstream Infections · Short Bowel Syndrome · Development
Primary: Number of Participants With Bloodstream Infections (BSI) — 0; 1 Participants
N/A N=120 Sacral Nerve Stimulation Therapy for the Treatment of Chronic Fecal Incontinence
Fecal Incontinence
Primary: Proportion of Subjects With at Least 50% Reduction in Number of Incontinent Episodes Per Week — 0.73 proportion of subjects — p=<0.0001
N/A N=293 Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants
Cholestasis · Cholestasis of Parenteral Nutrition
Primary: Time to Resolution of Parenteral Nutrition Associated Cholestasis Prior to End of Study — 38.02 Days
Phase 2 N=6 MTT for Children With Both Pitt Hopkins Syndrome and Gastrointestinal Disorders
Pitt Hopkins Syndrome
Primary: Daily Stool Record (DSR( — -2.3; 0 days
Phase 2 N=94 Inulin for Infections in the Intensive Care Unit
Antibiotic Resistant Infection · Nosocomial Infection · Pathogen Transmission
Primary: Within-individual Change in SCFA Producer Level — -0.0; -1.8; 1.1 percentage of SCFA producers
Phase 3 N=40 Prospective Randomized Clinical Trial of Intravenous Lipids and Cholestasis
Parenteral Nutrition Associated Cholestasis
Primary: Number of Participants With Parenteral Nutrition Associated Cholestasis — 6; 6 Participants — p=0.94
Phase 3 N=2 Omegaven as Alternative Parenteral Fat Nutrition
Cholestasis · Cholestasis of Parenteral Nutrition
Primary: Number of Participant With Decrease in Direct Bilirubin Level — 2; 0 Participants
Phase 2 N=23 Safety and Efficacy of Alemtuzumab in Pediatric Intestinal Transplantation
Evidence of Liver Transplantation · Rejection · ALEMTUZUMAB
Primary: Incidence of Post Transplant Lymphoproliferative Disorder (PTLD) — 6 participants
Phase 3 N=86 Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects
Short Bowel Syndrome
Primary: Responder — 27; 13 subjects — p=0.002
Phase 1 N=20 Gut Microbial Transplantation in Pediatric Inflammatory Bowel Diseases
Inflammatory Bowel Disease (IBD)
Primary: Clinical Response — 9 Participants — p=0.03
Phase 2 N=60 FMT in Cirrhosis and Hepatic Encephalopathy
Cirrhosis · Hepatic Encephalopathy
Primary: Serious Adverse Events Related to FMT — 0; 0; 0; 0 Participants
Phase 3 N=500 Supplemental Enteral Protein in Critical Illness
Nutrition Disorder · Trauma · Critical Illness
Primary: Serum Concentrations of Transthyretin at 3 Weeks After Injury. — 18.1; 18.9 mg/dl
N/A N=280 SANICS II Trial: Stimulation of the Autonomic Nervous System in Colorectal Surgery by Perioperative Nutrition
Postoperative Ileus · Anastomotic Leak
Primary: Number of Patients Developing Postoperative Ileus — 29; 37 Participants
Phase 3 N=150 Efficacy and Mechanisms of GLN Dipeptide in the SICU
Critical Illness
Primary: Hospital Mortality Rate — 11; 13 participants
Phase 3 N=50 Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE)
Hepatorenal Syndrome
Primary: Improvement of Renal Function (SCr) From Day 1 Thru End of Treatment, Repeated Measure Analysis. SCr Will be Collected Daily, From Day 1 Thru End of Treatment. Baseline…
Phase 2 N=15 Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis
Inflammatory Bowel Diseases · Ulcerative Colitis · Crohn Disease
Primary: 1. Safety and Tolerability of Universal Donor FMT Compared to Placebo: FMT-related Adverse Events Grade 2 or Above — 4; 0 Participants
N/A N=16 Diet Induced Intestinal Mucosal Adaptation
Healthy Conditions
Primary: Mucosal Surface Enlargement — 10.2; 9.9 percentage of muscular mucosae — p=<0.05
N/A N=4,561 Chronic Gastrointestinal Sequelae of an Acute Outbreak of Bacterial Gastroenteritis in Walkerton Ontario
Irritable Bowel Syndrome
Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants